about
Ion channels as drug targets in central nervous system disordersAntidepressant- and Anxiolytic-Like Effects of New Dual 5-HT₁A and 5-HT₇ Antagonists in Animal ModelsThe study of the lipophilicity of some aminoalkanol derivatives with anticonvulsant activity.HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in RatsPhysicochemical and biological evaluation of a cinnamamide derivative R,S-(2E)-1-(3-hydroxypiperidin-1-yl)-3-phenylprop-2-en-1-one (KM-608) for nervous system disorders.HBK-14 and HBK-15 with antidepressant-like and/or memory-enhancing properties increase serotonin levels in the hippocampus after chronic treatment in mice.Evaluation of anticonvulsants for possible use in neuropathic pain.Antimutagenic compounds and their possible mechanisms of action.Serotonergic system and its role in epilepsy and neuropathic pain treatment: a review based on receptor ligands.Cinnamamide Derivatives for Central and Peripheral Nervous System Disorders--A Review of Structure-Activity Relationships.Synthesis and activity of newly designed aroxyalkyl or aroxyethoxyethyl derivatives of piperazine on the cardiovascular and the central nervous systems.In vitro mutagenic, antimutagenic, and antioxidant activities evaluation and biotransformation of some bioactive 4-substituted 1-(2-methoxyphenyl)piperazine derivatives.HBK-7 - A new xanthone derivative and a 5-HT1A receptor antagonist with antidepressant-like properties.The antidepressant- and anxiolytic-like activities of new xanthone derivative with piperazine moiety in behavioral tests in mice.Chemically Homogenous Compounds with Antagonistic Properties at All α1-Adrenoceptor Subtypes but not β1-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in RatsAnticonvulsant evaluation of aminoalkanol derivatives of 2- and 4-methylxanthone.Synthesis and evaluation of pharmacological properties of some new xanthone derivatives with piperazine moiety.Contribution of reactive oxygen species to the anticancer activity of aminoalkanol derivatives of xanthone.Synthesis and in vitro Evaluation of the Anticancer Potential of New Aminoalkanol Derivatives of Xanthone.Anti-aggregation effect of aroxyalkyl derivatives of 2-methoxyphenylpiperazine is due to their 5-HT2A and α2-adrenoceptor antagonistic properties. A comparison with ketanserin, sarpogrelate, prazosin, yohimbine and ARC239.Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone.Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenylpiperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action.The antidepressant-like activity of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one involves serotonergic 5-HT(1A) and 5-HT(2A/C) receptors activation.Antidepressant-like activity of a new piperazine derivative of xanthone in the forced swim test in mice: The involvement of serotonergic system.HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels.Anti-Helicobacter pylori activities of selected N-substituted cinnamamide derivatives evaluated on reference and clinical bacterial strains.Effect of some newly synthesized xanthone and piperazine derivatives with cardiovascular activity on rheology of human erythrocytes in vitro.N-[(2,6-Dimethylphenoxy)alkyl]aminoalkanols-their physicochemical and anticonvulsant properties.Design, synthesis, and anticonvulsant activity of some derivatives of xanthone with aminoalkanol moieties.Anticonvulsant activity, crystal structures, and preliminary safety evaluation of N-trans-cinnamoyl derivatives of selected (un)modified aminoalkanols.Involvement of the NO/sGC/cGMP/K+ channels pathway in vascular relaxation evoked by two non-quinazoline α1-adrenoceptor antagonists.The nitric oxide/soluble cyclic guanylase/cyclic guanosine monophosphate pathway is involved in the cardiovascular effects of a novel α1- and β-adrenoceptor antagonistSynthesis and activity of di- or trisubstituted N -(phenoxyalkyl)- or N -{2-[2-(phenoxy)ethoxy]ethyl}piperazine derivatives on the central nervous systemHBK-14 and HBK-15, triple 5-HT 1A , 5-HT 7 and 5-HT 3 antagonists with potent antidepressant- and anxiolytic-like properties, increase seizure threshold in various seizure tests in miceDesign, synthesis and anticonvulsant-analgesic activity of new -[(phenoxy)alkyl]- and -[(phenoxy)ethoxyethyl]aminoalkanolsSynthesis and Evaluation of Antidepressant-like Activity of Some 4-Substituted 1-(2-methoxyphenyl)Piperazine DerivativesSynthesis and anticonvulsant activity of trans- and cis-2-(2,6-dimethylphenoxy)-N-(2- or 4-hydroxycyclohexyl)acetamides and their amine analogsSkin metabolism established with the use of MetaSite for selected retinoids employed in topical and systemic treatment of various skin disorders and found in cosmeceuticalsSimultaneous LC/ESI-MS separation method for the enantioseparation of some new anticonvulsant drugsDesign, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents
P50
Q27004533-BD545B57-0C38-44D2-B20E-2C1DD0023377Q28550792-B8B87294-E409-4A4F-A3BD-8959157CB671Q33641814-E4A86ACD-509B-4E65-B99A-266D68360CEEQ36176479-B6F7FF75-EBA7-4818-A0AE-05E3A2119284Q36252245-D3D21763-FE3E-436E-B4D2-DC89A14CF46EQ37694314-5A2CE4E7-CB3F-40C2-8CE2-E55A497211ECQ37921343-EC5BA69F-06A6-410C-9BE1-E3EDA2B19D70Q38194959-DF44865A-69CF-4FBD-960E-C7CF542B0942Q38269946-AF6BBB8E-1965-4E32-8D57-A9D9ABB654ABQ38530238-7A01096B-FAF5-4143-ABA2-F17302F560ACQ38737646-931BAC8A-A51A-46DB-BB32-E4202C0611A8Q38838563-98A1270A-F3F4-409D-B627-B6E86EE8955EQ38873393-5308D9A2-1D0F-40AA-8966-7DD6933011CCQ41931564-BFFEC541-CB4A-458A-8317-932D592A63E8Q42058859-21C636E7-E5F7-44FD-939D-B79D4A35F6F2Q43949642-859AD30E-A4F9-4C56-B780-7E129E853AA2Q44718659-4ACD6F7D-CE1F-428B-8435-1F8B982805F1Q46265828-03B7F94F-9E50-4F12-B68E-6F63FAAEE4B6Q46569770-B37CD388-33E7-4CD2-833E-D0B6CD658E01Q47810266-DE83BBBB-87A7-4BD4-91F1-9BA9C008E3CDQ47874568-C52B9A59-9EDD-4057-B66A-8796C58DB804Q48069023-E0B9BF58-DA16-4C4C-AD37-9CF41922C8FDQ48077440-643ADE78-A634-48AE-A2CF-B53775ED6D1AQ48140118-CBA72C7C-EB49-4922-845C-11F8D1C4AF9BQ48224914-9967E4E7-8220-4D96-BF7D-0EE620E6472AQ50025460-7BA87DF2-0431-4875-8BA9-F0872CEEB678Q50230007-8F18AFF7-A4C4-4C94-806B-2A7DE2E074FEQ51007062-FBFF7191-9198-4AC3-9A10-907BBB32BB15Q53031812-C31E5E1B-19CE-4485-82D2-9E8C7DD71308Q53280828-9620B88F-D9F6-4DC2-BD57-C317088B51AFQ53830412-63EF7BC0-F9CA-48BF-9CF4-AA32BC66960DQ57111935-E3939F82-33A7-4AD9-B9FD-AD58E18E2BB1Q63382949-E46458B3-800B-41B7-856E-642CAB5BE623Q63382951-2197E84D-2384-495C-9AAA-BD006BD1FB7EQ63382954-45848842-BDF6-4E4E-8640-83AE11BC52FBQ63382966-F26821ED-3818-40F7-BD0E-FE192DA81DC4Q85063943-B3FD07D6-608D-4616-ADE1-5124E5C2F420Q87083909-970239BE-C4BC-45FD-A8F8-9508D8B7F80CQ87203178-745C437A-F92F-407A-9A70-E7A644AB318EQ87483458-CCBC4168-F894-4084-BFDC-2F3C2AD7282F
P50
description
researcher ORCID ID = 0000-0002-2871-9418
@en
wetenschapper
@nl
name
Anna Waszkielewicz
@ast
Anna Waszkielewicz
@en
Anna Waszkielewicz
@es
Anna Waszkielewicz
@nl
Anna Waszkielewicz
@pl
type
label
Anna Waszkielewicz
@ast
Anna Waszkielewicz
@en
Anna Waszkielewicz
@es
Anna Waszkielewicz
@nl
Anna Waszkielewicz
@pl
altLabel
Anna Maria Waszkielewicz
@pl
prefLabel
Anna Waszkielewicz
@ast
Anna Waszkielewicz
@en
Anna Waszkielewicz
@es
Anna Waszkielewicz
@nl
Anna Waszkielewicz
@pl
P106
P1153
12783617900
P1559
Anna Waszkielewicz
@pl
P21
P31
P3124
P496
0000-0002-2871-9418